Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

John Gallacher*, Frederic de Reydet de Vulpillieres, Billy Amzal, Zuzanna Angehrn, Christin Bexelius, Christophe Bintener, Jacoline C. Bouvy, Laura Campo, Carlos Diaz, Jean Georges, Alastair Gray, Antje Hottgenroth, Pall Jonsson, Brent Mittelstadt, Michele H. Potashman, Catherine Reed, Cathie Sudlow, Robin Thompson, Antje Tockhorn-Heidenreich, Andrew TurnerJohan van der Lei, Pieter Jelle Visser, ROADMAP consortium

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

19 Citations (Web of Science)


ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.

Original languageEnglish
Pages (from-to)495-501
Number of pages7
JournalJournal of Alzheimer's Disease
Issue number2
Publication statusPublished - 2019


  • Alzheimer's disease
  • data sharing
  • data systems
  • health policy
  • patient outcome assessment
  • real-world clinical trials
  • systems integration

Cite this